Abstract
Background and Aim: Decompensated cirrhosis is defined in patients with cirrhosis as an acute deterioration of their liver function and is characterized for jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome (HRS) and varices. The aim of the study was to compare of Treatment of HBV decompensated Cirrhosis of Liver Patients by Tenofovir and Entecavir. Methods: The study was carried out at the inpatient department of hepatology, Bangabandhu Sheikh Mujib Medical University Hospital and Kurmitola General Hospital, Dhaka, Bangladesh. The study enrolled 100 treatment-naive patients with HBV decompensated cirrhosis of liver on Rntecavir or Tenofovir disoproxil fumarate from January 2013 to December 2018. Results: There are three follow up taken, first follow up was three months after medication. Second and third follow-up was after 06 months and 12-month completion of the treatment. In 3rd follow up (after one year), 100.0% patients were found undetected HBV DNA in Tenofovir group and 97.56% in Entecavir group. The difference was not statistically significant (p>0.05) between two groups. At 01-year total death was found 12 patients, out of them 03 was Tenofovir group and 06 was Entecavir group. In Tenofovir patients, Mean Child Pugh score was found 12.1±1.3 in pretreatment and 5.8±1.3 at 01 years. Mean MELD score was found 25.0±3.1 in pretreatment and 9.3±3.2 at 1 years. In Entecavir patients, Mean Child Pugh score was found 12.0±1.5 in pretreatment and 9.3±0.9 at 01 years. Mean MELD score was found 26.5±2.0 in pretreatment and 17.0±2.1 at 1 years. The difference of MELD and CTP score improvement was statistically significant (p<0.05) between two groups. Conclusions: Entecavir and Tenofovir both are good antiviral drugs for the treatment of HBV infection. In treatment of decompensated cirrhosis of liver Entecavir and Tenofovir both are significantly improved liver function, HBV DNA undetection and patient’s survival. But Tenofovir shown more improvement.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
